Get to know our clinical trials
A Phase I/IIa clinical trial of BI-1206, a monoclonal antibody targeting CD32b (Fc?RIIB), in combination with pembrolizumab, in patients with advanced solid tumors.
THE AIM IS TO DETERMINE WHETHER THE DRUG BI-1206, WHICH HAS NOT YET BEEN APPROVED FOR MARKETING, WILL BE EFFECTIVE IN TREATING ADVANCED SOLID TUMORS AND HOW SAFE IT IS FOR PEOPLE. IN THIS STUDY, BI-1206 WILL BE ADMINISTERED IN COMBINATION WITH PEMBROLIZUMAB, AN APPROVED DRUG MARKETED AS KEYTRUDA
Technical Summary
- PHASE I/IIA CLINICAL TRIAL OF BI-1206, A MONOCLONAL ANTIBODY AGAINST CD32B (FC?RIIB), IN COMBINATION WITH PEMBROLIZUMAB, IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2023-509846-36-00
- Protocol number: 18-BI-1206-03
- Promoter: BioInvent International AB
- Molecule/Drug: BI-1206 / Pembrolizumab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.